ME Research and Charts

ME - 23andMe Holding Co Class A (Healthcare: Diagnostics & Research)

Projected Earnings Date: 2024-08-29 (Delayed quote data 2025-01-03)

Last 3.79	Change ⇑ +0.24 (+6.76%)	Volume 288,683
	Open 3.57	High 3.82	Low 3.57

8EMA (Daily) 3.43	40EMA (Daily) 3.35	50EMA (Daily) 3.24	STO (Daily) 49.516	MACD Hist (Daily) 0.075
8EMA (Weekly) 3.433	40EMA (Weekly) 2.00	50EMA (Weekly) 1.85	STO (Weekly) 62.824	MACD Hist (Weekly) 0.048


Company Profile
23andMe Holding Co is a consumer genetics and research company. It helps people access, understand, and benefit from the human genome. Its research platform has generated various publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.